Works matching IS 01676997 AND DT 2024 AND VI 42 AND IP 1

Results: 15

Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 116, doi. 10.1007/s10637-024-01421-7

By:

Li, Meng-Ting;
He, Yang;
Huang, Si-Yong;
Hu, Xiao;
Chen, Ji-Sheng

Publication type:

Article

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 127, doi. 10.1007/s10637-024-01420-8

By:

Emiloju, Oluwadunni E.;
Yin, Jun;
Koubek, Emily;
Reid, Joel M.;
Borad, Mitesh J.;
Lou, Yanyan;
Seetharam, Mahesh;
Edelman, Martin J.;
Sausville, Edward A.;
Jiang, Yixing;
Kaseb, Ahmed O.;
Posey, James A.;
Davis, Sarah L.;
Gores, Gregory J.;
Roberts, Lewis R.;
Takebe, Naoko;
Schwartz, Gary K.;
Hendrickson, Andrea E. Wahner;
Kaufmann, Scott H.;
Adjei, Alex A.

Publication type:

Article

A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 106, doi. 10.1007/s10637-024-01417-3

By:

Yue, Jingying;
Shao, Shuai;
Zhou, Jie;
Luo, Wenting;
Xu, Yanling;
Zhang, Qinbin;
Jiang, Jing;
Zhu, Marie M

Publication type:

Article

Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 35, doi. 10.1007/s10637-023-01416-w

By:

Huynh, Jasmine C.;
Cho, May;
Monjazeb, Arta;
Al-Obeidi, Ebaa;
Singh, Amisha;
Tam, Kit;
Lara, Frances;
Martinez, Anthony;
Garcia, Leslie;
Kim, Edward J.

Publication type:

Article

Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 70, doi. 10.1007/s10637-023-01415-x

By:

Wang, Yue;
Lin, Xingyu;
Wang, Guan

Publication type:

Article

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 44, doi. 10.1007/s10637-023-01414-y

By:

Tsuji, Daiki;
Nakagaki, Shigeru;
Yonezawa, Itsuki;
Suzuki, Kenichi;
Yokokawa, Takashi;
Kawasaki, Yohei;
Yamaguchi, Takumi;
Kawaguchi, Takashi;
Hatori, Masahiro;
Matsumoto, Takuma;
Sakata, Yukio;
Yamamoto, Keisuke;
Nishimura, Tomoyasu;
Kogure, Yuki;
Hayashi, Toshinobu;
Osawa, Misa;
Itoh, Kunihiko;
Watanabe, Masaya

Publication type:

Article

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 60, doi. 10.1007/s10637-023-01413-z

By:

Jiang, Yanfang;
Hu, Xintong;
Wang, Zhouyu;
Zhang, Qin;
Chen, Dongsheng;
Zhao, Pingwei

Publication type:

Article

Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 53, doi. 10.1007/s10637-023-01412-0

By:

Lei, Haibo;
Sun, Wei;
Liu, Xiang;
Wang, Chunjiang

Publication type:

Article

Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 136, doi. 10.1007/s10637-023-01411-1

By:

Nogami, Naoyuki;
Tokito, Takaaki;
Zenke, Yoshitaka;
Satouchi, Miyako;
Seto, Takashi;
Saka, Hideo;
Ohtani, Junko;
Han, Shirong;
Noguchi, Kazuo;
Nishio, Makoto

Publication type:

Article

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 145, doi. 10.1007/s10637-023-01410-2

By:

Armstrong, Andrew J.;
Geva, Ravit;
Chung, Hyun Cheol;
Lemech, Charlotte;
Miller Jr., Wilson H.;
Hansen, Aaron R.;
Lee, Jong-Seok;
Tsai, Frank;
Solomon, Benjamin J.;
Kim, Tae Min;
Rolfo, Christian;
Giranda, Vincent;
Ren, Yixin;
Liu, Fang;
Kandala, Bhargava;
Freshwater, Tomoko;
Wang, Judy S.

Publication type:

Article

Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 89, doi. 10.1007/s10637-023-01409-9

By:

Afsharzadeh, Mahtab;
Varshosaz, Jaleh;
Mirian, Mina;
Hasanzadeh, Farshid

Publication type:

Article

Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 14, doi. 10.1007/s10637-023-01407-x

By:

Fletcher, Kelsey A.;
Alkurashi, Mai H.;
Lindsay, Andrew J.

Publication type:

Article

Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification: Immunoneoadjuvant therapy of gastric cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 1, doi. 10.1007/s10637-023-01406-y

By:

Yao, Guoliang;
Yuan, Jianyong;
Duan, Qianqian;
Tan, Yuan;
Zhang, Qin;
Chen, Dongsheng;
Chen, Jingbo

Publication type:

Article

Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 80, doi. 10.1007/s10637-023-01405-z

By:

Kim, Hyun Chul;
Yang, Eunsol;
Lee, Soyoung;
Oh, Jaeseong;
Lee, Myongjae;
Lee, ChaeEun;
Ha, Kyoung Soo;
Lee, Won Sik;
Jang, In-Jin;
Yu, Kyung-Sang

Publication type:

Article

Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 24, doi. 10.1007/s10637-023-01394-z

By:

Zhang, Changkun;
You, Xia;
Zhang, Qin;
Wang, Dong

Publication type:

Article